Market research
ZVSA ZyVersa Therapeutics Inc.
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 806K
- P/E ratio
- Not available
- Analyst target
- 20
- Dividend yield
- Not available
- Beta
- 0.86
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US98987D3008
- Market cap
- 806K
- P/E ratio
- Not available
- Analyst target
- 20
- Dividend yield
- Not available
- Beta
- 0.86
About
About ZyVersa Therapeutics Inc.
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100 a humanized monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of numerous inflammatory diseases, with cardiometabolic conditions associated with obesity as the lead. The company has a license agreement with L&F Research LLC, and InflamaCORE, LLC. ZyVersa Therapeutics, Inc. was founded in 2014 and is based in Weston, Florida.
Visit company websiteCommunity
Investor discussion
0 comments
Sign in to join the ZVSA discussion.
No comments yet
Start a focused discussion about ZVSA.